Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Genomics Nabs $3.5M in Series B Round

NEW YORK, Oct. 1 - Rubicon Genomics yesterday said it has secured $3.5 million in a Series B round of private-equity funding.


The Ann Arbor, Mich.-based company said it will use the cash to commercialize its OmniPlex technology. The round brings to $7.2 million Rubicon has pocketed since it was founded in 2000.


ARCH Development Partners led the round. Picking up the rear were Duchossois TECnology Partners, Sloan Ventures, and undisclosed individual investors.


Rubicon said OmniPlex is designed to allow researchers with a particular focus on diagnostics to amplify, archive, and analyze DNA.


Click here for more information.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.